Clinical and usability validation of gait velocity (SV95C) measured from wearable digital sensors

Active Cooperative Agreement Awarded

Award ID
U01FD009015
Recipient
Awarding agency
Obligated
$878,203

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 8% complete
Funding agency
Center for Drug Evaluation and Research Food and Drug Administration, Department of Health and Human Services
Place of performance
Boston, MA 02114, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Food and Drug Administration awarded $878,203 to The General Hospital Corporation, doing business as Massachusetts General Hospital, on September 23, 2026, under Cooperative Agreement U01FD009015. The award falls under Assistance Listing 93.103, Food and Drug Administration Research, and the source names the Center for Drug Evaluation and Research as the funding office. The recipient's Research Management Division is the award's recipient unit, and the place of performance is Boston, MA 02114. The ultimate completion date is August 31, 2028.

The project validates stride velocity 95th centile (SV95C), a gait velocity measure captured by wearable digital sensors, as a clinical trial endpoint in amyotrophic lateral sclerosis (ALS). It pursues three objectives: establishing construct validity and responsiveness relative to the ALSFRS-R and the 10-meter walk test; assessing the clinical significance and performance of SV95C as a trial endpoint using patient-reported outcomes; and gathering patient feedback on the measure's usability and clinical importance. The data generated will complete a regulatory-grade evidence package required by the European Medicines Agency and the FDA. The source states that the SysNav team has already completed verification and analytical validation work. The source names no sub-recipients for this award.

Description

Abstract
This grant proposal aims to establish clinical trial readiness for gait velocity, specifically the stride velocity 95TH centile (SV95C), measured by wearable digital sensors in patients with amyotrophic lateral sclerosis (ALS). With an increasingly active therapeutic pipeline for ALS, including innovative multi-arm trials, there is an urgent need for effective clinical trial endpoints that accurately capture treatment effects. The widely utilized ALS functional rating scale - revised (ALSFRS-R) has limitations, including being multidimensional and showing responsiveness issues. Metrics derived from wearable digital health technologies are emerging as promising options to complement the ALSFRS-R. SV95C, a novel wearable-derived measure, recently received regulatory approval as a primary efficacy endpoint for clinical trials in duchenne muscular dystrophy and is deemed well- suited for ALS due to its robustness against variability and its ability to capture clinically meaningful changes. This project aims to validate SV95C's utility in ALS through three key objectives: (1) establish its construct validity and responsiveness relative to traditional measures like ALSFRS-R and the 10-meter walk test; (2) assess the clinical significance and performance of SV95C as an endpoint in trials, using patient-reported outcomes capturing meaningful changes and key events; and (3) gather patient feedback on the usability and clinical importance of SV95C. The verification and analytical validation work has been completed by the sysnav team. This project will provide the data necessary to complete the regulatory grade evidence package required by both the european medicines agency (EMA) and the food and drug administration (FDA). Successfully validating SV95C could facilitate its acceptance as the first digital mobility endpoint in ALS, potentially leading to more efficient clinical trials by reducing required sample sizes and durations to determine meaningful treatment effects. This could enhance the landscape of ALS research, driving forward the development of new therapies for this challenging disease.

Quick answers

Who received award U01FD009015?

U01FD009015 was awarded to The General Hospital Corporation by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award U01FD009015 worth?

$878,203 has been obligated on U01FD009015.

Which agency awarded U01FD009015?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded U01FD009015, with funding from Center for Drug Evaluation and Research (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award